High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation.
about
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemiaTargeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinibThe role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemiaThe role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemiaPI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)The pathogenesis of chronic lymphocytic leukemiaAn open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemiaWhole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemiaStereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells.Using Murine Models to Investigate Tumor-Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma.BST-2/tetherin is overexpressed in mammary gland and tumor tissues in MMTV-induced mammary cancer.Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients.Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.CXCL12-induced chemotaxis is impaired in T cells from patients with ZAP-70-negative chronic lymphocytic leukemia.Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemiaThe bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease.CCL2 in chronic lymphocytic leukemia: a macro in microenvironment?Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia.Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 studyB-cell receptor signaling as a driver of lymphoma development and evolution.The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphomaSuppression of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycle.CLL cells respond to B-Cell receptor stimulation with a microRNA/mRNA signature associated with MYC activation and cell cycle progressionOSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cellsGuilty bystanders: nurse-like cells as a model of microenvironmental support for leukemic lymphocytes.Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemiaPTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse modelRewiring of sIgM-mediated intracellular signaling through the CD180 Toll-like receptor.Interleukin 21 Controls mRNA and MicroRNA Expression in CD40-Activated Chronic Lymphocytic Leukemia CellsCCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemiaUnder the microscope: CCL3 and T cells in the microenvironment of chronic lymphocytic leukemia.Haematological malignancies: at the forefront of immunotherapeutic innovation.Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic LeukemiaPhysical contact with endothelial cells through β1- and β2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells.Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
P2860
Q24599100-C20E941A-194E-44E4-AF0B-885842431344Q26744277-8A1226C1-CC6D-4FCC-B5D8-70F1EA37290BQ26751006-AF06F06C-978C-4633-91B3-D925619C411BQ26775506-697758F0-99B7-4068-99D5-ED11C8CA0F57Q26782633-AE9E8ADA-0C32-4768-BDC8-8B17EC0CD19EQ27025715-6205AAD2-2B3B-4CE6-8D5D-BEC857FEF6ACQ28257366-33AEDCB9-5704-49BC-B386-52DE62D12BA9Q29614659-5904F2C1-E45B-4B10-995B-E1AB7A275435Q30994095-EE0E83EF-2348-4BB5-8569-FF4EC438581AQ33621881-5CBF2305-AB7C-4859-B81B-30A3959AF9CDQ33631179-53608042-8E21-4462-A7D5-519BF25E4AADQ33648906-5EBDFE3B-97B2-42AA-B47F-AC296FDEF9B9Q33745075-DB2D889F-6558-464D-9495-161D24B703A7Q33829089-B0F2ED2F-A159-49AB-9641-E0B9F13B05E8Q33873323-F8DE6F82-BB30-4100-9140-916AE8DEB459Q33924158-5EE543D4-F37D-41DA-8FEA-FFFDD08F523BQ33934606-1E7630E5-3C2C-4321-BCB4-7CA58ED4D073Q34008559-02D471C8-D0E2-4569-B47A-933C01E66A8CQ34009041-6428FB7B-7614-44B7-8584-2BAB8E897797Q34029869-FACF0EA6-C860-43BC-A6CB-370F96DB4FDEQ34056568-3589B8BC-5E2B-46CD-88F2-D94882E3E81AQ34240404-CB784502-9674-4316-8016-AE4DA560005CQ34398579-E7E6D2F6-07A6-40EE-B7F4-8C0127F4BB25Q34542102-28AD9EFA-BA86-4B93-AC7B-8CF188C8A5BCQ34626318-01256345-5CF5-4929-9D8A-7500204F8C11Q34650591-7E37A459-CA1E-4416-96BF-C5FD31E6A76CQ34656369-1C1CA925-FE86-4CD9-9FB8-FA0C98E38905Q34876742-0F1A28ED-BAF4-4D6C-A4A6-309853BE02A7Q35020381-761F9EF0-C12D-433C-89E7-2D6D124A9319Q35553576-22D93AF6-C1DB-4081-8DA3-A78E90D102F1Q35685290-A6577CD1-0B72-48D5-9BD4-0BC622AFC35CQ35707093-E0D696FC-662D-41EC-976C-FD088BCBF40EQ35754594-3DCB8943-D04E-4669-98FB-7C923140D66CQ35868355-1F82B0C1-D67A-46D1-8427-9A5DC3796305Q35876037-F58FE039-3B54-42E2-B328-D50BC09DF472Q35880618-A5E381D2-A633-40FC-9BA6-9D8725E74CC5Q35958056-9FAAF6A2-E059-48B0-AB06-EF4FA9FDEF3BQ36006453-073A9FD2-905C-45C3-B9CA-79D954CDDBFEQ36020943-F19A562C-2CA0-45FE-8DAC-AA0C3763A981Q36021849-898684CB-79C6-4DAA-A006-9822F1F877D2
P2860
High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
High-level expression of the T ...... res and after BCR stimulation.
@en
High-level expression of the T ...... res and after BCR stimulation.
@nl
type
label
High-level expression of the T ...... res and after BCR stimulation.
@en
High-level expression of the T ...... res and after BCR stimulation.
@nl
prefLabel
High-level expression of the T ...... res and after BCR stimulation.
@en
High-level expression of the T ...... res and after BCR stimulation.
@nl
P2093
P2860
P1433
P1476
High-level expression of the T ...... res and after BCR stimulation.
@en
P2093
Andrea Bürkle
Andreas Rosenwald
Elena Hartmann
Jan A Burger
Maite P Quiroga
P2860
P304
P356
10.1182/BLOOD-2008-07-170415
P407
P577
2008-12-12T00:00:00Z